Libertex Adds Cutting-Edge Crypto Arbitrum to Its CFD Trading Platform
Libertex, the online trading platform for retail and professional traders, has just launched an exciting new underlying asset that grants traders a superb opportunity to trade the future of cryptocurrency – Arbitrum CFDs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005969/en/
(Graphic: Business Wire)
About Arbitrum
Arbitrum is a layer-2 scaling solution for Ethereum that runs its own blockchain. Designed to improve upon the base Ethereum functionality that supports smart contracts, NFTs and dApps, Arbitrum is creating a buzz among crypto and institutional investors in the finance world because of the advantages it offers compared to older crypto solutions. These include:
- Faster transactions – Arbitrum can process 40,000 transactions per second compared to just 14 on Ethereum. This makes it much more capable of upscaling than Ethereum and its competitors.
- Lower fees – Due to its highly efficient optimistic rollup technology, transactions that would cost several dollars to complete on Ethereum only cost around two cents on Arbitrum.
- Market share – Arbitrum's appeal is backed up by the numbers. It is the leading layer-2 solution, claiming over 66% of the market in terms of total value locked. There are over 4 million unique Arbitrum addresses and more than 400 Arbitrum dApps, including many popular platforms such as GMX, Uniswap and Camelot.
- Developer-friendly – Arbitrum is fully compatible with the Ethereum Virtual Machine (EVM) and popular programming languages. It comes with documentation for developers and doesn't need any plugins or extras for developing Ethereum-based apps.
- Governance functionality – Arbitrum tokens (ARB) will be used for governance within the Arbitrum DAO, granting holders a voice and stake in the future of the project.
- Track NFTs in real time – The latest feature to be added to Arbitrum is the ability to receive real-time notifications when an NFT changes addresses, as well as the option to track and follow trends using the Alchemy platform. This makes it especially useful for anyone involved in the NFT marketplace.
Arbitrum continues to add new features that make it an even bigger player in the crypto world. Traders now have a chance to join this project's exciting journey by trading Arbitrum CFDs with Libertex without needing to buy or hold the ARB token itself.
Trade for More with Libertex
Recognising the importance of cryptocurrency as an exciting new industry sector for traders, Libertex features no commissions, swap or exchange fees and ultra-low spreads on all crypto CFDs, making it one of the best places to trade crypto CFDs. To find out more about Libertex, visit libertex.com or download the mobile app for iOS on the App Store or for Android on Google Play or AppGallery.
Part of the Libertex Group, Libertex is an online broker offering tradable CFDs with underlying assets being commodities, Forex, ETFs, cryptocurrencies and others. Libertex also offers investments in real stocks.
Over the years, Libertex has received more than 40 prestigious international awards and recognitions, including "Best CFD Broker Europe" (Global Brands Magazine, 2022) and "Most Trusted Broker in Europe" (Ultimate Fintech Awards, 2021). Libertex is the Official Online Trading Partner of FC Bayern and Tottenham Hotspur, bringing the exciting worlds of football and trading together.
Since being founded in 1997, the Libertex Group has grown into a diverse group of companies, serving millions of clients from several countries all over the world.
In Europe, the Libertex trading platform is operated by Indication Investments Ltd., a Cyprus Investment Firm regulated and supervised by the Cyprus Securities and Exchange Commission (CySEC) with CIF License number 164/12.
Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 85.9% of retail investor accounts lose money when trading CFDs with this provider. Tight spreads apply. Please check our spreads on the platform. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005969/en/
Contact information
Press Contact:
Action PR
Evri Fotiadou
evri.f@actionprgroup.com
phone: +357 22 818724
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ilsong Educational Foundation Chairman Dai-Won Yoon Wins Linnaeus Medal as the First in Asia2.6.2023 12:00:00 EEST | Press release
On May 30, Chairman Dai-Won Yoon of Ilsong Educational Foundation received the Linnaeus Medal from Uppsala University at Hallym University. This makes him the first person from Asia to receive the award. Ilsong Educational Foundation operates Hallym University and Hallym University Medical Center. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531005495/en/ Chairman Dai-Won Yoon (left) of Ilsong Educational Foundation received Linnaeus Medal as the 1st in Asia (Photo: Hallym University) Chairman Yoon is the honoree of 2020. The award ceremony, which had been postponed due to COVID-19, was held this year with a delegation led by Vice Chancellor Anders Hagfeldt of Uppsala University visiting Korea. The Linnaeus Medal to commemorate Carl Linnaeus, a Swedish botanist, is awarded annually by Uppsala University to a person who has made a significant contribution to the field of science. Chairman Yoon was honored for his work in
10th Annual World Patient Safety, Science & Technology Summit Begins2.6.2023 09:15:00 EEST | Press release
Day one of the 10th Annual World Patient Safety, Science & Technology Summit presented by the Patient Safety Movement Foundation (PSMF) saw global leaders across the world of patient safety call for an increased urgency in addressing the issue of preventable harm within healthcare. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601006140/en/ Joe Kiani, founder of the Patient Safety Movement Foundation, speaks at the 10th Annual World Patient Safety, Science & Technology Summit in Newport Beach, California. (Photo: Business Wire) Celebrating the PSMF’s 10th anniversary, Dr. Michael Ramsay, chief executive officer of the PSMF, reflected on the role that the increasing availability of hospital data on medical errors could play in reducing harm. “I’m very optimistic that we’re really going to see a difference in healthcare,” he said. “Technology is changing. We’re now getting real data. We know what the outcomes are in hospit
Autel Energy Holds Partner Summit in Amsterdam, Mapping Out Europe Strategy2.6.2023 09:00:00 EEST | Press release
Autel Energy, a leading provider of EV charging products and services, successfully hosted the Autel Partner Summit at Muziekgebouw in Amsterdam from May 31 to June 1, 2023. The event not only showcased Autel’s visionary Europe strategy for the next two years but also provided partners opportunities to gain insights into the company's vision, and learn about Autel’s new products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005428/en/ A quick afternoon bite with the Autel partners. (Photo: Business Wire) The Partner Summit helped Autel Energy to strengthen its partnerships in Europe and highlighted its collaborations with key clients. Notable partners in attendance included Maxicharger AC clients such as Sevadis and Deta, as well as Maxicharger DC clients such as Floading, Gasgas, and eWays. The company also partnered with CPO clients like Fastway and Powerdo, as well as energy companies like Enefit. The Summit was d
PL BioScience and Macopharma enter into a Patent License and Assignment Agreement regarding Human Platelet Lysate (HPL) cell culture supplements.2.6.2023 08:22:00 EEST | Press release
PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a Patent License and Assignment Agreement with the French company Macopharma S.A.S. As a result of the Agreement, PL BioScience will hereby accept a worldwide license under the patents filed by Macopharma, with a right to sublicense (through multiple tiers), for the duration of the license period. In addition to the Patent License and Assignment Agreement, Macopharma will introduce PL BioScience to their current HPL customers, and thanks to a comprehensive comparative evaluation showing equivalence of HPL products from PL BioScience, Macopharma HPL customers will have the opportunity to transfer their future orders to PL BioScience with minimal disruption. About PL BioScience: Located in Aachen in Germany, PL BioScience GmbH is a life science company specializing in the production and development of Human Platelet Lysate (HP
AOP Health: Completed Study Strengthens Clinical Development Program for ropeginterferon alpha 2b (Besremi®) in polycythaemia vera2.6.2023 05:00:00 EEST | Press release
With the publication of the final results from the LOW-PV study in the New England Journal of Medicine Evidence conducted by Fondazione per la Ricerca dell'Ospedale di Bergamo (FROM) under the leadership of Professor Tiziano Barbui, AOP Health announces an important advancement reinforcing its clinical development program for ropeginterferon alpha-2b (BESREMi®) in polycythaemia vera (PV), a rare blood cancer. The academic LOW-PV study supported and funded by AOP Health and public organizations in Italy complements a series of trials performed by AOP Health over more than 10 years to achieve marketing authorization in Europe and the Middle East. With these clinical studies, including PEGINVERA, PROUD-PV, and CONTINUATION-PV, AOP Health opened a new area of treatment options for patients suffering from PV. A further study (PEN-PV) was performed to develop a pen for self-injection allowing ease of self-administration, exact dosing and minimal waste of the medical product. AOP Health’s com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom